FY2024 EPS Estimates for Genelux Increased by HC Wainwright

Genelux Co. (NASDAQ:GNLX) – Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Genelux in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.84) per share for the year, up from their previous forecast of ($0.88). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $1.23 EPS.

Genelux Trading Down 5.3 %

Shares of GNLX opened at $3.03 on Thursday. The business’s 50 day moving average is $4.05 and its 200 day moving average is $3.09. Genelux has a 12-month low of $1.60 and a 12-month high of $6.50. The company has a market capitalization of $104.65 million, a PE ratio of -3.19 and a beta of -1.41.

Institutional Investors Weigh In On Genelux

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Genelux during the fourth quarter worth $25,000. Apollon Wealth Management LLC lifted its stake in Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after purchasing an additional 2,857 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Genelux during the 4th quarter valued at about $41,000. Brown Brothers Harriman & Co. grew its position in shares of Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after purchasing an additional 9,114 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new stake in shares of Genelux in the fourth quarter worth about $51,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.